Elias Kouchakji
Net Worth
Last updated:
What is Elias Kouchakji net worth?
The estimated net worth of Dr. Elias Kouchakji is at least $6,679,234 as of 17 Nov 2020. He owns shares worth $1,190,269 as insider, has earned $129,285 from insider trading and has received compensation worth at least $5,359,680 in FibroGen, Inc..
What is the salary of Elias Kouchakji?
Dr. Elias Kouchakji salary is $893,280 per year as Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance in FibroGen, Inc..
How old is Elias Kouchakji?
Dr. Elias Kouchakji is 69 years old, born in 1956.
What stocks does Elias Kouchakji currently own?
As insider, Dr. Elias Kouchakji owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| FibroGen, Inc. (FGEN) | Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance | 109,199 | $10.9 | $1,190,269 |
What does FibroGen, Inc. do?
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Elias Kouchakji insider trading
FibroGen, Inc.
Dr. Elias Kouchakji has made only one insider trade between 2019-2020, according to the Form 4 filled with the SEC.
As of 17 Nov 2020 he still owns at least 109,199 units of FGEN stock.
FibroGen key executives
FibroGen, Inc. executives and other stock owners filed with the SEC:
- Dr. Elias Kouchakji (69) Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance
- Dr. Mark Eisner M.D., M.P.H. (59) Chief Medical Officer
- Mr. Enrique A. Conterno (58) Chief Executive Officer & Director
- Mr. James A. Schoeneck (67) Chairman
- Mr. Pat Cotroneo (61) Executive Advisor to Chief Executive Officer
- Mr. Thane Wettig (60) Chief Commercial Officer